Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN RUBINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962543280
CMS profile
43312
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,823.22

39 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,012.33 4
Food and Beverage $810.89 35

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN RUBINO

NPI 1962543280 · CMS profile ID 43312

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–39 of 39 matching records. This page contains 39 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1962543280?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

39 matching records · $1,823.22 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 39 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–39 of 39.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $11.8412/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250837 CMS
Amarin Pharma Inc. $12.3912/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699282451 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.7511/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681998927 CMS
Merck Sharp & Dohme Corporation $10.7411/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695868903 CMS
AstraZeneca Pharmaceuticals LP $14.0111/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685718589 CMS
AbbVie, Inc. $15.5810/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648088187 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.5910/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700276625 CMS
Novo Nordisk Inc $12.9610/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674975467 CMS
Amgen Inc. $17.1210/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547099 CMS
Astellas Pharma US Inc $20.7110/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 655746611 CMS
Janssen Pharmaceuticals, Inc $12.5809/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250829 CMS
Gilead Sciences, Inc. $12.2809/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681595261 CMS
GlaxoSmithKline, LLC. $11.0108/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671434051 CMS
Amarin Pharma Inc. $16.2208/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699203747 CMS
Lilly USA, LLC $10.9508/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657914525 CMS
Amgen Inc. $13.4307/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547122 CMS
Radius Health, Inc. $17.2007/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683933285 CMS
Daiichi Sankyo Inc. $16.6007/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695326079 CMS
Gilead Sciences, Inc. $17.5106/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681595259 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.3406/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700276627 CMS
Amarin Pharma Inc. $17.7605/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699150335 CMS
Amgen Inc. $12.3605/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547119 CMS
Janssen Pharmaceuticals, Inc $13.9304/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250819 CMS
PFIZER INC. $47.1304/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673769553 CMS
Merck Sharp & Dohme Corporation $9.3104/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695400809 CMS
Amgen Inc. $13.1303/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547115 CMS
PFIZER INC. $264.0503/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673245891 CMS
PFIZER INC. $224.8703/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673246889 CMS
PFIZER INC. $476.2803/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673246891 CMS
PFIZER INC. $329.9203/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673247255 CMS
AstraZeneca Pharmaceuticals LP $11.3203/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685750651 CMS
Amgen Inc. $13.5103/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547111 CMS
Kowa Pharmaceuticals America, Inc. $10.8402/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 630297057 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $20.3302/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684914617 CMS
Novartis Pharmaceuticals Corporation $17.3402/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659852577 CMS
Merck Sharp & Dohme Corporation $12.8001/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695918117 CMS
Amgen Inc. $13.3501/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662547107 CMS
Janssen Pharmaceuticals, Inc $11.2201/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659250815 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.9601/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700276629 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.22 39
PY2020 $410.97 28
PY2021 $698.79 47
PY2022 $543.04 31
PY2023 $6,389.49 35
PY2024 $1,915.52 44
PY2025 $1,251.65 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,783,192.12 359
PY2024 Recipient $66,231.01 15
PY2024 Principal investigator $2,510,578.54 317
PY2023 Recipient $6,417.61 4
PY2023 Principal investigator $2,159,960.11 267
PY2022 Principal investigator $2,441,546.83 286
PY2021 Principal investigator $1,166,336.49 169
PY2020 Principal investigator $1,326,147.90 192
PY2019 Principal investigator $636,986.48 193

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

192 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan, Inc. $200.00 12/31/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721314455
Principal investigator 1 Allergan, Inc. $600.00 12/31/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721316799
Principal investigator 1 PFIZER INC. $1,338.54 12/29/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742896577
Principal investigator 1 Kowa Research Institute, Inc. $693.00 12/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671215
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 12/21/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201933
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 12/21/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737201937
Principal investigator 1 PFIZER INC. $34,634.98 12/19/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742896581
Principal investigator 1 PFIZER INC. $3,823.20 12/16/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742896837
Principal investigator 1 Allergan, Inc. $1,190.35 12/15/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721312999
Principal investigator 1 PFIZER INC. $892.36 12/12/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742896911
Principal investigator 1 Esperion Therapeutics, Inc. $300.00 12/11/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737200765
Principal investigator 1 Allergan, Inc. $552.00 12/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721311363
Principal investigator 1 PFIZER INC. $2,166.20 12/05/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742895745
Principal investigator 1 PFIZER INC. $661.50 12/03/2020 Non-covered Recipient Entity
PMG Research of Charlotte LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742896841
Principal investigator 1 PFIZER INC. $15,633.00 12/03/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742896905
Principal investigator 1 PFIZER INC. $1,323.00 12/03/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742896907
Principal investigator 1 Kowa Research Institute, Inc. $2,655.00 12/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671203
Principal investigator 1 PFIZER INC. $9,811.38 11/28/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742910983
Principal investigator 1 Novartis Pharmaceuticals Corporation $179.37 11/25/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A RANDOMIZED DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER TRIAL ASSESSING THE IMPACT OF LIPOPROTEIN (A) LOWERING WITH TQJ230 ON MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 721494671
Principal investigator 1 PFIZER INC. $1,302.75 11/21/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742854439
Principal investigator 1 PFIZER INC. $1,984.50 11/21/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907819
Principal investigator 1 PFIZER INC. $13,445.52 11/21/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742909827
Principal investigator 1 PFIZER INC. $1,984.50 11/19/2020 Non-covered Recipient Entity
PMG Research of Charlotte LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742907205
Principal investigator 1 PFIZER INC. $21,090.70 11/17/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742910681
Principal investigator 1 Allergan, Inc. $738.15 11/16/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721308163
Principal investigator 1 PFIZER INC. $22,654.64 11/07/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742906877
Principal investigator 1 PFIZER INC. $50.00 11/05/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742906889
Principal investigator 1 PFIZER INC. $375.00 11/05/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907773
Principal investigator 1 PFIZER INC. $65.00 11/05/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742908485
Principal investigator 1 Kowa Research Institute, Inc. $828.00 11/03/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671209
Principal investigator 1 PFIZER INC. $22,730.38 10/31/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742906217
Principal investigator 1 PFIZER INC. $7,000.00 10/29/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742854815
Principal investigator 1 PFIZER INC. $1,586.49 10/29/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742856199
Principal investigator 1 PFIZER INC. $1,984.50 10/29/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907079
Principal investigator 1 Merck Sharp & Dohme Corporation $5,920.80 10/28/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721887
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 10/26/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737196319
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 10/26/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737196322
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 10/26/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737196325
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 10/26/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737196331
Principal investigator 1 PFIZER INC. $1,057.66 10/26/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855869
Principal investigator 1 PFIZER INC. $54,371.43 10/23/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742909331
Principal investigator 1 PFIZER INC. $28,472.00 10/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742908573
Principal investigator 1 PFIZER INC. $1,498.40 10/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909819
Principal investigator 1 PFIZER INC. $57,971.60 10/20/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742911253
Principal investigator 1 PFIZER INC. $528.83 10/19/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 742855871
Principal investigator 1 PFIZER INC. $1,323.00 10/17/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742911183
Principal investigator 1 Allergan, Inc. $738.15 10/16/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721303307
Principal investigator 1 PFIZER INC. $33,156.44 10/10/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742911639
Principal investigator 1 PFIZER INC. $94,461.60 10/02/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742912315
Principal investigator 1 Esperion Therapeutics, Inc. $100.00 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737195031
Principal investigator 1 PFIZER INC. $750.00 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742906675
Principal investigator 1 PFIZER INC. $130.00 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742906707
Principal investigator 1 PFIZER INC. $3,307.50 10/01/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907341
Principal investigator 1 PFIZER INC. $100.00 10/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907377
Principal investigator 1 PFIZER INC. $119,469.26 09/26/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742910919
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 09/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194779
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 09/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194783
Principal investigator 1 Esperion Therapeutics, Inc. $689.00 09/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194787
Principal investigator 1 Esperion Therapeutics, Inc. $256.00 09/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFECTS OF BEMPEDOIC ACID (ETC-1002) ON THE OCCURRENCE OF MAJOR CARDIOVASCULAR EVENTS IN PATIENTS WITH, OR AT HIGH RISK FOR, CARDIOVASCULAR DISEASE WHO ARE STATIN INTOLERANT No dispute reported 06/30/2026 737194791
Principal investigator 1 Kowa Research Institute, Inc. $1,485.90 09/24/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671185
Principal investigator 1 Novo Nordisk AS $500.00 09/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336839
Principal investigator 1 Novo Nordisk AS $1,000.00 09/22/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336841
Principal investigator 1 PFIZER INC. $7,890.28 09/19/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909981
Principal investigator 1 PFIZER INC. $89,233.34 09/19/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742911005
Principal investigator 1 Allergan, Inc. $738.15 09/15/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721297677
Principal investigator 1 PFIZER INC. $83,487.19 09/12/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742911925
Principal investigator 1 PFIZER INC. $66,881.20 09/10/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742906753
Principal investigator 1 Allergan, Inc. $2,662.90 09/03/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721295379
Principal investigator 1 Novo Nordisk AS $26,310.22 09/01/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336837
Principal investigator 1 PFIZER INC. $66,881.20 08/29/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742908969
Principal investigator 1 Kowa Research Institute, Inc. $1,589.40 08/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671191
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,425.00 08/25/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
MULTI-CENTER CROSS-SECTIONAL EPIDEMIOLOGICAL STUDY TO CHARACTERIZE THE PREVALENCE AND DISTRIBUTION OF LIPOPROTEIN(A) LEVELS AMONG PATIENTS WITH ESTABLISHED CARDIOVASCULAR DISEASE No dispute reported 06/30/2026 721494157
Principal investigator 1 PFIZER INC. $26,752.48 08/22/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742906479
Principal investigator 1 Allergan, Inc. $225.00 08/21/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721291987
Principal investigator 1 Allergan, Inc. $276.00 08/21/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721292321
Principal investigator 1 PFIZER INC. $3,969.00 08/19/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909277
Principal investigator 1 Allergan, Inc. $656.25 08/18/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721290815
Principal investigator 1 Allergan, Inc. $2,062.45 08/13/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721290149
Principal investigator 1 PFIZER INC. $50.00 08/13/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742906779
Principal investigator 1 PFIZER INC. $65.00 08/13/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909110
Principal investigator 1 PFIZER INC. $375.00 08/13/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909815
Principal investigator 1 PFIZER INC. $3,969.00 07/31/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742908517
Principal investigator 1 Kowa Research Institute, Inc. $3,210.30 07/27/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671197
Principal investigator 1 PFIZER INC. $20,776.50 07/17/2020 Non-covered Recipient Entity
PMG Research of Charlotte LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742911877
Principal investigator 1 PFIZER INC. $8,140.28 07/17/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742912533
Principal investigator 1 Ferring Pharmaceuticals AS $1,197.50 07/16/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721460089
Principal investigator 1 Merck Sharp & Dohme Corporation $182.40 07/15/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721755
Principal investigator 1 Allergan, Inc. $738.15 07/14/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721284085
Principal investigator 1 PFIZER INC. $10,500.00 07/11/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 742911279
Principal investigator 1 PFIZER INC. $65.00 07/09/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907399
Principal investigator 1 PFIZER INC. $375.00 07/09/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907739
Principal investigator 1 PFIZER INC. $100.00 07/09/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909757
Principal investigator 1 PFIZER INC. $50.00 07/09/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909759
Principal investigator 1 PFIZER INC. $5,655.78 07/02/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742908481
Principal investigator 1 Kowa Research Institute, Inc. $4,419.00 06/25/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671179
Principal investigator 1 Allergan, Inc. $500.00 06/16/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721279971
Principal investigator 1 Allergan, Inc. $1,000.00 06/16/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721279975
Principal investigator 1 Allergan, Inc. $738.15 06/16/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721280335
Principal investigator 1 PFIZER INC. $8,111.68 06/16/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742910935
Principal investigator 1 Merck Sharp & Dohme Corporation $1,839.80 06/12/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721753
Principal investigator 1 Merck Sharp & Dohme Corporation $1.50 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721757
Principal investigator 1 Merck Sharp & Dohme Corporation $1.95 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721791
Principal investigator 1 Merck Sharp & Dohme Corporation $11.56 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721793
Principal investigator 1 Merck Sharp & Dohme Corporation $181.50 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721795
Principal investigator 1 Merck Sharp & Dohme Corporation $2.40 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721797
Principal investigator 1 Merck Sharp & Dohme Corporation $24.20 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721799
Principal investigator 1 Merck Sharp & Dohme Corporation $396.00 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721801
Principal investigator 1 Merck Sharp & Dohme Corporation $4.95 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721835
Principal investigator 1 Merck Sharp & Dohme Corporation $50.40 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721837
Principal investigator 1 Merck Sharp & Dohme Corporation $59.40 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721839
Principal investigator 1 Merck Sharp & Dohme Corporation $6.46 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721841
Principal investigator 1 Merck Sharp & Dohme Corporation $8.08 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721843
Principal investigator 1 Merck Sharp & Dohme Corporation $1.05 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721845
Principal investigator 1 Merck Sharp & Dohme Corporation $14.25 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721881
Principal investigator 1 Merck Sharp & Dohme Corporation $46.75 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721883
Principal investigator 1 Merck Sharp & Dohme Corporation $9.68 06/08/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721885
Principal investigator 1 PFIZER INC. $20,973.30 06/04/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742911667
Principal investigator 1 Allergan, Inc. $400.00 06/01/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721278283
Principal investigator 1 PFIZER INC. $10,067.58 05/29/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907139
Principal investigator 1 Novo Nordisk AS $1,824.77 05/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336829
Principal investigator 1 Novo Nordisk AS $187.50 05/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336831
Principal investigator 1 Novo Nordisk AS $187.50 05/26/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336833
Principal investigator 1 PFIZER INC. $6,686.24 05/21/2020 Non-covered Recipient Entity
PMG Research of Charlotte LLC
A PHASE 12 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING FIRSTINHUMAN STUDY TO DESCRIBE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 742907853
Principal investigator 1 PFIZER INC. $788.74 05/15/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742910409
Principal investigator 1 Allergan, Inc. $1,610.25 05/14/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721275401
Principal investigator 1 Allergan, Inc. $660.00 05/12/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721274209
Principal investigator 1 Kowa Research Institute, Inc. $1,335.60 05/12/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671173
Principal investigator 1 PFIZER INC. $9,632.67 05/02/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742910665
Principal investigator 1 PFIZER INC. $6,765.16 04/30/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742910107
Principal investigator 1 Kowa Research Institute, Inc. $693.00 04/27/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671169
Principal investigator 1 Novo Nordisk AS $75.00 04/27/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336835
Principal investigator 1 Novo Nordisk AS $4,588.72 04/23/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336827
Principal investigator 1 PFIZER INC. $961.88 04/22/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742908337
Principal investigator 1 PFIZER INC. $14,407.14 04/21/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742910637
Principal investigator 1 PFIZER INC. $150.00 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907049
Principal investigator 1 PFIZER INC. $195.00 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907263
Principal investigator 1 PFIZER INC. $1,125.00 04/08/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909997
Principal investigator 1 Allergan, Inc. $1,000.00 04/01/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721268005
Principal investigator 1 Allergan, Inc. $7,000.00 04/01/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721268009
Principal investigator 1 Kowa Research Institute, Inc. $3,229.20 04/01/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671163
Principal investigator 1 Merck Sharp & Dohme Corporation $1,475.00 03/27/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721617
Principal investigator 1 Merck Sharp & Dohme Corporation $300.00 03/27/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721655
Principal investigator 1 PFIZER INC. $480.94 03/26/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909395
Principal investigator 1 PFIZER INC. $500.00 03/26/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909895
Principal investigator 1 Novo Nordisk AS $6,442.54 03/24/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336825
Principal investigator 1 Allergan, Inc. $3,970.05 03/19/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721266117
Principal investigator 1 PFIZER INC. $12,459.48 03/19/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742911457
Principal investigator 1 Allergan, Inc. $4,298.75 03/16/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721264421
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,268.67 03/11/2020 Non-covered Recipient Entity
Pmg Research Of Raleigh LLC
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 751191511
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $26,137.86 03/09/2020 Non-covered Recipient Entity
PMG Research Inc
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 751190731
Principal investigator 1 PFIZER INC. $7,739.88 02/28/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907379
Principal investigator 1 Novo Nordisk AS $7,114.73 02/25/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336823
Principal investigator 1 Allergan, Inc. $9,854.35 02/24/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721259049
Principal investigator 1 PFIZER INC. $5,508.32 02/21/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909957
Principal investigator 1 Kowa Research Institute, Inc. $3,829.50 02/20/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671157
Principal investigator 1 PFIZER INC. $1,125.00 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742906327
Principal investigator 1 PFIZER INC. $150.00 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909025
Principal investigator 1 PFIZER INC. $240.47 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909369
Principal investigator 1 PFIZER INC. $195.00 02/19/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742912016
Principal investigator 1 Allergan, Inc. $738.15 02/14/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721257551
Principal investigator 1 Merck Sharp & Dohme Corporation $100.80 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721659
Principal investigator 1 Merck Sharp & Dohme Corporation $11.40 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721661
Principal investigator 1 Merck Sharp & Dohme Corporation $2.10 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721663
Principal investigator 1 Merck Sharp & Dohme Corporation $20.40 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721701
Principal investigator 1 Merck Sharp & Dohme Corporation $28.50 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721703
Principal investigator 1 Merck Sharp & Dohme Corporation $3.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721705
Principal investigator 1 Merck Sharp & Dohme Corporation $363.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721707
Principal investigator 1 Merck Sharp & Dohme Corporation $792.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721709
Principal investigator 1 Merck Sharp & Dohme Corporation $82.50 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721711
Principal investigator 1 Merck Sharp & Dohme Corporation $9.90 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721747
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721749
Principal investigator 1 Merck Sharp & Dohme Corporation $3.90 02/10/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721751
Principal investigator 1 PFIZER INC. $480.94 02/06/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742906397
Principal investigator 1 PFIZER INC. $50.00 02/06/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742908191
Principal investigator 1 PFIZER INC. $65.00 02/06/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909989
Principal investigator 1 PFIZER INC. $375.00 02/06/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742911745
Principal investigator 1 PFIZER INC. $11,516.64 02/01/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742909215
Principal investigator 1 Novo Nordisk AS $9,158.13 01/28/2020 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4375 No dispute reported 06/30/2026 742336821
Principal investigator 1 Kowa Research Institute, Inc. $2,529.00 01/24/2020 Non-covered Recipient Entity
PMG RESEARCH INC
K-877-302 No dispute reported 06/30/2026 721671151
Principal investigator 1 Allergan, Inc. $13,342.75 01/22/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721249735
Principal investigator 1 Merck Sharp & Dohme Corporation $1,400.00 01/22/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721615
Principal investigator 1 Merck Sharp & Dohme Corporation $2,365.00 01/22/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721619
Principal investigator 1 PFIZER INC. $2,416.70 01/22/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742908507
Principal investigator 1 PFIZER INC. $480.94 01/17/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742911157
Principal investigator 1 Allergan, Inc. $1,498.15 01/15/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, OPEN-LABEL 40-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH MIGRAINE No dispute reported 06/30/2026 721248087
Principal investigator 1 Merck Sharp & Dohme Corporation $4,126.00 01/13/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721657
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 01/09/2020 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH, LLC
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 740721665
Principal investigator 1 PFIZER INC. $13,068.70 01/08/2020 Non-covered Recipient Entity
PMG Research of Raleigh LLC
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF 2 DOSES COMPARED TO 3 DOSES OF CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 742907759
Principal investigator 1 Allergan, Inc. $5,000.00 01/03/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721245309
Principal investigator 1 Ferring Pharmaceuticals AS $1,706.20 01/02/2020 Non-covered Recipient Entity
PMG RESEARCH INC
A Randomised, Double-blind, Placebo-controlled, Response-adaptive Dose-finding Trial Investigating the Efficacy, Safety and Tolerability of Oral Doses of FE 201836, With Desmopressin Orally Disintegrating Tablet as a Benchmark, During 12 Weeks of Treatment for Nocturia Due to Nocturnal Polyuria in Adults No dispute reported 06/30/2026 721459435
Principal investigator 1 Allergan, Inc. $400.00 01/01/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721245067
Principal investigator 1 Allergan, Inc. $2,500.00 01/01/2020 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PATIENTS WITH EPISODIC MIGRAINE No dispute reported 06/30/2026 721245071